RxDoctor Payments Data

Steven Koh, MD

Family Medicine · Edmonds, WANPI 1114114535

Payments from drug & device makers

$1,187in general payments, 2019–2025

Across 43 payments — averaging $27.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$345
  • Novo Nordisk$199
  • Johnson & Johnson$145
  • Biohaven Pharmaceuticals, Inc.$144
  • Aimmune Therapeutics, Inc.$74
  • Nestle Healthcare Nutrition Inc.$49
  • plus $232 from 7 others

What the payments were for

  • Food & beverage$1,187100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,187 in reported general payments places this provider in the 85th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$15,974
Medicare patients
54
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase124$327,527
JanuviaSitagliptin Phosphate46$71,958
EliquisApixaban32$39,029
XareltoRivaroxaban16$24,533
ProliaDenosumab14$23,729
JardianceEmpagliflozin16$21,670
TrulicityDulaglutide19$17,382
RestasisCyclosporine16$15,720
ArexvyRsvpref3 Antigen/As01e/Pf23$6,614
ShingrixVaricella-Zoster Ge/As01b/Pf24$5,012
Atorvastatin Calcium674$4,247
Losartan Potassium457$3,928
Lidocaine39$3,769
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$3,442
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$3,386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Restasis$345$343,247140 claims
PfizerEliquis$49$39,02932 claims
Johnson & JohnsonXarelto$145$24,53316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Edmonds

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →